공고 • Jun 13
ORIENT BIO Inc., Annual General Meeting, Jun 29, 2026 ORIENT BIO Inc., Annual General Meeting, Jun 29, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 322, galmachi-ro, jungwon-gu, gyeonggi-do, seongnam South Korea Board Change • Jun 09
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. 1 independent director (3 non-independent directors). Independent Outside Director Yong-Seok Cho was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. New Risk • Feb 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩83.6b market cap, or US$58.2m). 공고 • Jun 12
ORIENT BIO Inc., Annual General Meeting, Jun 27, 2025 ORIENT BIO Inc., Annual General Meeting, Jun 27, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 322, galmachi-ro, jungwon-gu, gyeonggi-do, seongnam South Korea New Risk • Jun 02
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩132.6b (US$96.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risk Market cap is less than US$100m (₩132.6b market cap, or US$96.5m). New Risk • Mar 25
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩143.7b (US$98.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Market cap is less than US$100m (₩143.7b market cap, or US$98.2m). New Risk • Dec 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩71.3b market cap, or US$50.3m). 공고 • Jun 15
ORIENT BIO Inc., Annual General Meeting, Jun 28, 2024 ORIENT BIO Inc., Annual General Meeting, Jun 28, 2024, at 09:01 Tokyo Standard Time. Location: conference room, 322, galmachi-ro, jungwon-gu, gyeonggi-do, seongnam South Korea Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 20
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₩8.00 (down from ₩34.00 in 3Q 2021). Revenue: ₩17.2b (up 22% from 3Q 2021). Net income: ₩940.0m (down 77% from 3Q 2021). Profit margin: 5.5% (down from 29% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Reported Earnings • Nov 19
Second quarter 2022 earnings released: ₩2.00 loss per share (vs ₩81.00 loss in 2Q 2021) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2022 results: Revenue: ₩14.5b (up 21% from 2Q 2021). Net loss: ₩221.1m (loss narrowed 98% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 23
First quarter 2022 earnings released: EPS ₩23.00 (vs ₩4.00 loss in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₩13.5b (up 13% from 1Q 2021). Net income: ₩2.69b (up ₩3.07b from 1Q 2021). Profit margin: 20% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Reported Earnings • Jun 30
Full year 2021 earnings released: ₩135 loss per share (vs ₩116 loss in FY 2020) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: ₩52.0b (up 40% from FY 2020). Net loss: ₩15.3b (loss widened 27% from FY 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 19
Third quarter 2021 earnings released: EPS ₩34.00 (vs ₩4.00 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₩14.1b (up 35% from 3Q 2020). Net income: ₩4.08b (up ₩4.98b from 3Q 2020). Profit margin: 29% (up from net loss in 3Q 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Jan 15
New 90-day high: ₩1,950 The company is up 21% from its price of ₩1,610 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is up 16% over the same period. Is New 90 Day High Low • Dec 23
New 90-day low: ₩1,230 The company is down 13% from its price of ₩1,415 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 14% over the same period. Is New 90 Day High Low • Nov 25
New 90-day low: ₩1,405 The company is down 33% from its price of ₩2,100 on 28 August 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 2.0% over the same period. Reported Earnings • Nov 20
Second quarter 2021 earnings released: ₩81.00 loss per share The company reported a solid second quarter result with improved revenues and control over expenses, though losses increased. Second quarter 2021 results: Revenue: ₩12.0b (up 54% from 2Q 2020). Net loss: ₩9.07b (loss widened 42% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. 공고 • Sep 21
ORIENT BIO Inc.(KOSE:A002630) dropped from S&P Global BMI Index ORIENT BIO Inc.(KOSE:A002630) dropped from S&P Global BMI Index 공고 • Aug 06
ORIENT BIO Inc. announced that it has received KRW 11.67259512 billion in funding from MDAS Inc., Orient Precision Industries Inc. On August 5, 2020, ORIENT BIO Inc. (KOSE:A002630) closed the transaction. 공고 • Jul 31
ORIENT BIO Inc. (KOSE:A002630) agreed to acquire an additional 29.74% stake in Orient Electronics Co.,Ltd. for KRW 6.7 billion. ORIENT BIO Inc. (KOSE:A002630) agreed to acquire an additional 29.74% stake in Orient Electronics Co.,Ltd. for KRW 6.7 billion on July 28, 2020. As part of the transaction, ORIENT BIO Inc. will acquire 3,774,092 stocks in Orient Electronics Co.,Ltd. Board of directors of ORIENT BIO Inc. resolved the transaction and date of acquisition is August 5, 2020.